ANOTHER EXPERIMENTAL MEDICATION “ASTRAZENECA” ACQUIRED THE "BREAKTHROUGH" STATUS

The world's leading pharmaceutical company “AstraZeneca” shared the news the FDA called its product "breakthrough" again. This product is the second drug acquired such a status in a short time. The first drug “Imfinzi” has been developed for the treatment of lung cancer, the second one - for the treatment of blood cancer (“Acalabrutinib”).
“Acalabrutinib” is an inhibitor of Bruton tyrosine-kinase (TKB). It has been developed to treat many types of B-cell cancer in patients who have previously received at least one course of therapy.
The “Acalabrutinib” drug was called "breakthrough" by the data of phase II clinical trial ACE-LY-004. Patients with recurrent or refractory mantle cell lymphoma (MRL), an aggressive form of B-cell non-Hodgkin's lymphoma, participated in this research. Also, the new drug test for use as a monotherapy and in combination with other drugs to treat several types of blood cancer, as well as solid/substantial tumours. ”Acalabrutinib” is being studied for the treatment of chronic lymphocytic leukaemia (CLL), and there are preliminary positive results.
Statements on  http://pharma.net.ua
Link to the original http://pharma.net.ua/news/world/17936-amerikanskie-vlasti-prisvoili-status-proryvnogo-esche-odnomu-eksperimentalnomu-preparatu-astrazeneca

BaDM - We work for you!

Regional offices